A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)

PHASE3RecruitingINTERVENTIONAL

Enrollment

424

Participants

Timeline

Start Date

August 20, 2023

Primary Completion Date

August 30, 2025

Study Completion Date

August 30, 2027

Conditions

TNBC - Triple-Negative Breast Cancer

Interventions

DRUG

Camrelizumab Plus Chemotherapy and Famitinib

camrelizumab+chemotherapy (Albumin-paclitaxel plus carboplatin)+Famitinib

DRUG

Camrelizumab Plus Chemotherapy

Trial Locations (2)

RECRUITING

Breast cancer institute of Fudan University Cancer Hospital, Shanghai

RECRUITING

Fudan University Shanghai Cancer Center Shanghai, China, 200032, Shanghai

All Listed Sponsors

lead

Fudan University

OTHER